WO2006029605A1 - Procede et principe actif pour lutter contre les plasmodies - Google Patents

Procede et principe actif pour lutter contre les plasmodies Download PDF

Info

Publication number
WO2006029605A1
WO2006029605A1 PCT/DE2005/001610 DE2005001610W WO2006029605A1 WO 2006029605 A1 WO2006029605 A1 WO 2006029605A1 DE 2005001610 W DE2005001610 W DE 2005001610W WO 2006029605 A1 WO2006029605 A1 WO 2006029605A1
Authority
WO
WIPO (PCT)
Prior art keywords
plants
active ingredient
malaria
pharmaceutical active
ingredient according
Prior art date
Application number
PCT/DE2005/001610
Other languages
German (de)
English (en)
Inventor
Dirk Weikmann
Original Assignee
Toximed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toximed Gmbh filed Critical Toximed Gmbh
Priority to DE112005002874T priority Critical patent/DE112005002874A5/de
Publication of WO2006029605A1 publication Critical patent/WO2006029605A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the most dangerous form is the malaria tropica, which can even lead to death if left untreated.
  • the transmission of malaria takes place via a bite of the Anopheles mosquito.
  • the characteristic symptom of malaria is periodic fever.
  • the diagnosis of the disease is based on the symptoms and a microscopic examination of the blood.
  • Prophylaxis includes the avoidance of mosquito bites and the use of various medications in the form of tablets.
  • malaria also called marsh or intermittent fever
  • malaria includes several febrile diseases caused by parasitic unicellular organisms of the genus Plasmodium.
  • the name malaria derives from Latin and is associated with the idea of "bad air” in wetlands.
  • Malaria tropica The malaria tropica is considered the most dangerous of the malaria diseases. Untreated, it causes death in about 30% of cases.
  • the pathogen Plasmodium falciparum leads to malaria tropica.
  • the pathogen Plasmodium vivax leads to malaria tertiana.
  • the pathogen Plasmodium ovale leads to malaria tertiana.
  • the pathogen Plasmodium malariae leads to malaria quartana.
  • the developmental cycle of all malaria parasites is divided into a sexual cycle that takes place in the carrier mosquito and an asexual cycle that occurs in humans. This change between sexual and asexual reproduction is called a generational change.
  • the sexual cycle is the same in all malaria parasites.
  • the female and male plasmoplants the gametes, unite.
  • the mosquito has to absorb the precursors of these gametes, the gametocytes, from an infected person.
  • the male gametes fertilize the female gametes and several intermediate stages of development follow: Gamet - zygote - ookinet - oocyst - sporozoite, which are not to be described in detail here.
  • the developmental cycle in the Anopheles mosquito lasts between 8 and 16 days, depending on the outside temperature.
  • the last stage of development of the malaria parasite in the Anopheles mosquito, the sporozoite passes from the salivary glands of the mosquito into the blood of humans during the next suction act and enters the asexual development cycle there.
  • isoniazid interrupts the developmental cycle of malaria-causing plasmodia in the mosquito.
  • isoniazid can be used in combination with known anti - malarial drugs.
  • Another method is known from DE 198 12 590 A1, a method for controlling and killing human - animal and phytopathogenic microorganisms from the series of insects and worms, in which a bringing and introducing an aqueous percarboxylic acid solution containing one or more percarboxylic acids with 1 to 6 C atoms, on surfaces and / or waters.
  • the description also includes, inter alia, the control of the malaria-transmitting Anopheles mosquito.
  • the method of the invention, or the active ingredient used is therefore the object of eliminating the cause of malaria in an environmentally friendly manner.
  • the malaria-causing plasmodia are to a large extent already in the
  • Plasmodium be killed in the mosquito or its larvae.
  • the feed used in accordance with the invention is essentially powdered toxic milk juice from plants of the genus Euphorbia.
  • biogenic toxins such as the above-mentioned milk juice
  • biogenic poisons Needs-matched, so-called biogenic, poisons. These biogenic poisons have found their place in the course of long development periods in the interplay of different types of life.
  • Plants or animals may be primarily toxic through the production of toxins, or secondary to toxicity by ingesting toxic substances from the living or inanimate environment.
  • DE 199 61 141 A1 discloses a pharmaceutical active ingredient in which it has been found that constituents of spider venoms from spiders of the family Sicaridae can be used for the treatment of tumor diseases.
  • a peptide toxin from the venom of this spider species another antagonistic substance obtained from the venom and / or a combination of these constituents are used medicinally in the main. It can be used for the treatment of tumor diseases as well as parallel or supportive to tumor operations and residual tumor tissue can be destroyed.
  • genetically modified body cells tumor cells
  • the total toxin content of this spider species, a cocktail of various substances so to speak, is not pharmaceutically usable due to its lethal effect even in small doses.
  • biogenic poisons derived from plants can also be used to produce active pharmaceutical ingredients for combating pathogens.
  • Euphorbia alfredii Rauh b) Euphorbia ambroseae LCLearch c) Euphorbia ampliphylla Pax d) Euphorbia baga A.Chevallier e) Euphorbia brunelli Chiovenda f) Euphorbia cooperi NEBrown ex A.Berger g) Euphorbia espinosa Pax h) Euphorbia goetzei Pax i) Euphorbia knuthii Pax j) Euphorbia tirucalli Linne '
  • the plants according to the invention belong to the family Euphoriaceae
  • the wolf milk plants are one of the largest families in the plant kingdom and with approx. 7500 kinds in 300 kinds to mostly well-known large families like the basket flower plants (Asteraceae, 22000
  • the juice is milk white and coagulates into a latex.
  • the toxicity is weak, but some are highly dangerous.
  • Succulent plants are plants that have adapted in the course of their development to a life in the drylands of the earth. That happened by this
  • Plant normal plant organs such as stem, leaf or petiole or roots
  • the plants mentioned under a) to j) are to be cultivated in the substrates in which they also grow in their natural habitat. It is also possible to use in the pot a purely mineral substrate which the person skilled in the art can select from the offer on the market in order to obtain the substances suitable for the respective plants.
  • the development and production of the larvae feed according to the invention takes place in the following manner:

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un procédé pour lutter contre les plasmodies, responsables de la malaria, par traitement des larves du moustique anophèle avec un principe actif extrait de plantes de la famille des euphorbiacées.
PCT/DE2005/001610 2004-09-14 2005-09-14 Procede et principe actif pour lutter contre les plasmodies WO2006029605A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE112005002874T DE112005002874A5 (de) 2004-09-14 2005-09-14 Verfahren und Wirkstoff zur Bekämpfung von Plasmodien

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004044428.5 2004-09-14
DE102004044428A DE102004044428A1 (de) 2004-09-14 2004-09-14 Verfahren und pharmazeutischer Wirkstoff zur Bekämpfung von Plasmodien

Publications (1)

Publication Number Publication Date
WO2006029605A1 true WO2006029605A1 (fr) 2006-03-23

Family

ID=35385172

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2005/001610 WO2006029605A1 (fr) 2004-09-14 2005-09-14 Procede et principe actif pour lutter contre les plasmodies

Country Status (2)

Country Link
DE (2) DE102004044428A1 (fr)
WO (1) WO2006029605A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108157391A (zh) * 2017-12-26 2018-06-15 重庆医学检验试剂研究所 一种抑制蚊子幼虫羽化的试剂及其应用
CN108157400A (zh) * 2017-12-26 2018-06-15 重庆医学检验试剂研究所 一种抑制蚊子排卵的试剂及其应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009000716A1 (de) 2009-02-09 2010-08-12 Robert Bosch Gmbh Verfahren zum Bestimmen eines Erfassungsfehlers für einen Drehwinkel einer Welle

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2175502A (en) * 1985-04-03 1986-12-03 Roussel Uclaf Inhibiting the development of protozoa
WO1995010626A1 (fr) * 1993-10-14 1995-04-20 Centre De Cooperation Internationale En Recherche Agronomique Pour Le Developpement Procede pour la transformation enzymatique des triglycerides d'une matiere grasse, en particulier la matiere grasse laitiere
US6432452B1 (en) * 1997-08-19 2002-08-13 Peplin Biotech Pty. Ltd. Anti-cancer compounds
US20030166613A1 (en) * 2000-06-07 2003-09-04 Aylward James Harrison Therapeutic agents - I

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2175502A (en) * 1985-04-03 1986-12-03 Roussel Uclaf Inhibiting the development of protozoa
WO1995010626A1 (fr) * 1993-10-14 1995-04-20 Centre De Cooperation Internationale En Recherche Agronomique Pour Le Developpement Procede pour la transformation enzymatique des triglycerides d'une matiere grasse, en particulier la matiere grasse laitiere
US6432452B1 (en) * 1997-08-19 2002-08-13 Peplin Biotech Pty. Ltd. Anti-cancer compounds
US20030166613A1 (en) * 2000-06-07 2003-09-04 Aylward James Harrison Therapeutic agents - I

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BOTANICAL JOURNAL OF THE LINNEAN SOCIETY, vol. 94, no. 4, 1987, pages 453 - 464, ISSN: 0024-4074 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1977, LEACH L C: "EUPHORBIA SPECIES FROM THE FLORA ZAMBESIACA AREA PART 12", XP002358608, Database accession no. PREV197764067202 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1987, NEWTON L E: "AN AMPLIFIED DESCRIPTION OF EUPHORBIA-BAGA CHEVALIER EUPHORBIACEAE WITH NOTES ON VARIATION AND DESCRIPTION ON A NEW VARIETY", XP002358607, Database accession no. PREV198784073867 *
FAGBENRO-BEYIOKU A F ET AL: "DISINFECTANT/ANTIPARASITIC ACTIVITIES OF JATROPHA CURCAS", EAST AFRICAN MEDICAL JOURNAL, KENYA MEDICAL ASSOCIATION HOUSE, KE, vol. 75, no. 9, September 1998 (1998-09-01), pages 508 - 511, XP009057946, ISSN: 0012-835X *
KIRKIA, vol. 10, no. 2, 1977, pages 391 - 400, ISSN: 0451-9930 *
TONA L ET AL: "ANTIMALARIAL ACTIVITY OF 20 CRUDE EXTRACTS FROM NINE AFRICAN MEDICINAL PLANTS USED IN KINSHASA, CONGO", JOURNAL OF ETHNOPHARMACOLOGY, ELSEVIER SCIENTIFIC PUBLISHERS LTD, IE, vol. 68, no. 1-3, 15 December 1999 (1999-12-15), pages 193 - 203, XP009057935, ISSN: 0378-8741 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108157391A (zh) * 2017-12-26 2018-06-15 重庆医学检验试剂研究所 一种抑制蚊子幼虫羽化的试剂及其应用
CN108157400A (zh) * 2017-12-26 2018-06-15 重庆医学检验试剂研究所 一种抑制蚊子排卵的试剂及其应用

Also Published As

Publication number Publication date
DE102004044428A1 (de) 2006-03-30
DE112005002874A5 (de) 2007-08-30

Similar Documents

Publication Publication Date Title
DE2832204A1 (de) Mittel zur behandlung von nervenerkrankungen, verfahren zu seiner herstellung und seine verwendung
CN106511267A (zh) 复方莫昔克丁滴剂及其制备方法和应用
WO2006029605A1 (fr) Procede et principe actif pour lutter contre les plasmodies
DE60124516T2 (de) Kombination des lezithins mit ascorbinsäure
DE102005038768A1 (de) Pharmazeutischer Wirkstoff gegen Borreliose
CN106692171B (zh) 宠物用复方赛拉菌素外用滴剂及其方法和应用
Molefe Anthelmintic, anticancer and phytochemical screening of Cotyledon orbiculata; Hermannia depressa; Nicotiana glauca and potassium permanganate
EP2155335B1 (fr) Composition pharmaceutique, utilisation de la composition pharmaceutique pour le traitement d'une tumeur du cerveau, procédé de fabrication de cette composition et kit contenant la composition pharmaceutique
EP1754486A2 (fr) Substance pharmaceutique pour le traitement de l'Hépatitis, Borreliosis et Sclèrosis Multiple
Susilowati et al. Efficacy of Shampoo Made from Bangle Rhizome Extract (Zingiber montanum) Against Head Lice (Pediculus humanus capitis)
WO2005009449A1 (fr) Principe actif pharmaceutique agissant contre les verrues, l'herpes et le zona
Sarath A Comparative Clinical Study of Shigruadi Lepa and Padmaka Lepa in Vrischika Damsha
EP1699472A1 (fr) Agent actif pharmaceutique contre le cancer du sein
Viana EFFECT OF CASEARIA SYLVESTRIS OIL IN CHRONIC INFLAMMATION INDUCED BY SYNTHETIC IMPLANTS IN MICE
WO1994018957A2 (fr) Utilisation de substances actives en therapie de certaines maladies, procede de preparation d'une composition pharmaceutique utile a cet effet et compositions pharmaceutiques ainsi preparees
Michalczyk et al. The impact of pollen on the health status of animals and humans
RU2136303C1 (ru) Способ получения средства для лечения ларвального и стробилярного эхинококкозов "чеблин ск-1"
EP4233886A1 (fr) Composition pharmaceutique pour le traitement d'une tumeur cérébrale
WO2004108147A1 (fr) Principe pharmaceutique
DE10324861A1 (de) Pharmazeutischer Wirkstoff
WO2007065925A2 (fr) Composition pour traiter des melanomes et des impuretes de la peau, et cosmetique de soin cutane
WO2007071716A1 (fr) Composition pharmaceutique utilisee pour traiter des tumeurs et des maladies virales definies
EP1699471A1 (fr) Agent pharmaceutique contre l'hepatite
DE2811520A1 (de) Anthelmintisches topicum
DE10331957A1 (de) Pharmarzeutischer Wirkstoff gegen Magengeschwüre

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1120050028747

Country of ref document: DE

REF Corresponds to

Ref document number: 112005002874

Country of ref document: DE

Date of ref document: 20070830

Kind code of ref document: P

122 Ep: pct application non-entry in european phase